EUVIMEDEUVIMED entdecken
Open Access

A whole-cell pertussis vaccine engineered to elicit reduced reactogenicity protects baboons against pertussis challenge

Parul Kapil, Yihui Wang iD, Kelsey Gregg iD, Lindsey Zimmerman, Damaris Molano, Jonatan Maldonado Villeda, Peter Sebo iD, Tod J Merkel iD

mSphere · 21.11.2024 · 9 (11)

DOI: 10.1128/msphere.00647-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, erschienen am 21.11.2024. Verfasst von Parul Kapil und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Pertussis Vaccine, Whooping Cough, Papio. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Virology and Microbiology, Food and Drug Administration and by the National Institutes of Health Division of Microbiology and Infectious Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Whole-cell pertussis (wP) vaccines introduced in the 1940s led to a dramatic reduction of pertussis incidence and are still widely used in low- and middle-income countries (LMICs) worldwide. The reactogenicity of wP vaccines resulted in reduced public acceptance, which drove the development and introduction of acellular pertussis (aP) vaccines in high-income countries in the 1990s. Increased incidence of pertussis disease has been observed in high-income countries following the introduction of aP vaccines despite near universal rates of pediatric vaccination. These increases are attributed to the reduced protection against colonization, carriage, and transmission as well as reduced duration of immunity conferred by aP vaccines relative to the wP vaccines they replaced. A reduced reactogenicity whole-cell pertussis (RRwP) vaccine was recently developed with the goal of achieving the same protection as conferred by wP vaccination but with an improved safety profile, which may benefit countries in which wP vaccines are still in routine use. In this study, we tested the RRwP vaccine in a baboon model of pertussis infection. We found that the RRwP vaccine induced comparable cellular and humoral immune responses and comparable protection following challenge relative to the wP vaccine, while significantly reducing injection-site reactogenicity. IMPORTANCE The World Health Organization (WHO) recommended in 2015 that countries administering wP vaccines in their national vaccine programs should continue to do so, and that switching to aP vaccines for primary infant immunization should only be considered if periodic booster vaccinations and/or maternal immunization could be assured and sustained in their national immunization schedules (WHO, Vaccine 34:1423–1425, 2016, https://doi.org/10.1016/j.vaccine.2015.10.136 ). Due to the considerably higher cost of aP vaccines and the larger number of doses required, most LMICs continue to use wP vaccines. The development and introduction of a wP vaccine that induces fewer adverse events without sacrificing protection would significantly benefit countries in which wP vaccines are still in routine use. The results of this study indicate this desirable goal may be achievable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pertussis VaccineWhooping CoughPapioAnimalsAntibodies, BacterialFemaleDisease Models, AnimalBordetella pertussisVaccinationMale

Stichwörter der Autor:innen

baboon modelpertussiswhole cell vaccines

Substanzen

Pertussis VaccineAntibodies, Bacterial

Autor:innen und Institutionen

  • Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA.
  • Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.

ORCID-Profile: Yihui Wang, Kelsey Gregg, Peter Sebo, Tod J Merkel

Förderung

  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute of Virology and Microbiology
  • Food and Drug Administration and by the National Institutes of Health Division of Microbiology and Infectious Disease

Zitieren

APA

Kapil, P., Wang, Y., Gregg, K., Zimmerman, L., Molano, D., Maldonado Villeda, J., Sebo, P., & Merkel, T. J. (2024). A whole-cell pertussis vaccine engineered to elicit reduced reactogenicity protects baboons against pertussis challenge. mSphere, 9(11). https://doi.org/10.1128/msphere.00647-24

Vancouver

Kapil P, Wang Y, Gregg K, Zimmerman L, Molano D, Maldonado Villeda J, et al. A whole-cell pertussis vaccine engineered to elicit reduced reactogenicity protects baboons against pertussis challenge. mSphere. 2024;9(11). doi:10.1128/msphere.00647-24

BibTeX
@article{Kapil2024,
  author = {Kapil, Parul and Wang, Yihui and Gregg, Kelsey and Zimmerman, Lindsey and Molano, Damaris and Maldonado Villeda, Jonatan and Sebo, Peter and Merkel, Tod J},
  title = {A whole-cell pertussis vaccine engineered to elicit reduced reactogenicity protects baboons against pertussis challenge},
  journal = {mSphere},
  year = {2024},
  volume = {9},
  number = {11},
  doi = {10.1128/msphere.00647-24}
}
Kostenlos starten →